1. Deep Sequencing Analysis Reveals That KRAS Mutation Is a Marker of Poor Prognosis in Patients with Pulmonary Sarcomatoid Carcinoma 
Filippo Lococo, MD, Greta Gandolfi, PhD, Giulio Rossi, MD, Carmine Pinto, MD, Cristian Rapicetta, MD, Alberto Cavazza, MD, Alfredo Cesario, MD, Carla Galeone, Massimiliano Paci, MD, Alessia Ciarrocchi, PhD 
Journal of Thoracic Oncology 
Volume 11, Issue 8, Pages (August 2016)
DOI: /j.jtho
Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

2. Figure 1
(A and B) Type of mutation according to the type of nucleotide substitution (A) and the variant consequence (B) in 72 somatic mutation events detected in the pulmonary sarcomatoid carcinomas (PSCs). (C) Frequency of mutated samples for each gene. Frequency of mutations in pure PSCs and biphasic (intermingled with non–small cell lung cancer component) PSCs (D) and in our cohort of PSCs compared with lung adenocarcinomas and lung squamous cell carcinomas according to The Cancer Genome Atlas data (E). (F–I) Kaplan-Meier plots for association of tumor stage (F), presence of mutations (G), occurrence of Kirsten rat sarcoma viral oncogene homolog gene (KRAS) mutation (H), and occurrence of either KRAS or tumor protein p53 gene (TP53) mutations (I) with patient survival. PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene; STK11, serine/threonine kinase 11 gene; APC, adenomatous polyposis coli gene; PTEN, phosphatase and tensin homolog gene; BRAF, B-Raf proto-oncogene, serine/threonine kinase gene; EGRF, epidermal growth factor receptor gene; FBXW7, F-box and WD repeat domain containing 7 gene; FOXL2, forkhead box L2; MET, MMNG HOS Transforming gene; NRAS, neuroblastoma RAS viral (v-ras) oncogene homolog gene; SMAD4, SMAD family member 4 gene.
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions